U.S. Markets closed

Recent Analysis Shows Lattice Semiconductor, ZIOPHARM Oncology, Ferro, SYNNEX, AxoGen, and Twin Disc Market Influences — Renewed Outlook, Key Drivers of Growth

NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Lattice Semiconductor Corporation ( LSCC ), ZIOPHARM Oncology Inc ( ZIOP ), Ferro Corporation ( FOE ), SYNNEX Corporation ( SNX ), AxoGen, Inc. ( AXGN ), and Twin Disc, Incorporated ( TWIN ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

LSCC DOWNLOAD: http://Capital-Review.com/register/?so=LSCC
ZIOP DOWNLOAD: http://Capital-Review.com/register/?so=ZIOP
FOE DOWNLOAD: http://Capital-Review.com/register/?so=FOE
SNX DOWNLOAD: http://Capital-Review.com/register/?so=SNX
AXGN DOWNLOAD: http://Capital-Review.com/register/?so=AXGN
TWIN DOWNLOAD: http://Capital-Review.com/register/?so=TWIN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Lattice Semiconductor Corporation ( LSCC ), ZIOPHARM Oncology Inc ( ZIOP ), Ferro Corporation ( FOE ), SYNNEX Corporation ( SNX ), AxoGen, Inc. ( AXGN ), and Twin Disc, Incorporated ( TWIN ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 12th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

LATTICE SEMICONDUCTOR CORPORATION (LSCC) REPORT OVERVIEW

Lattice Semiconductor's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Lattice Semiconductor reported revenue of $101.48MM vs $91.97MM (up 10.34%) and analysts estimated basic earnings per share $0.05 vs -$0.35. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Lattice Semiconductor reported revenue of $385.96MM vs $427.05MM (down 9.62%) and analysts estimated basic earnings per share -$0.58 vs -$0.45. Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.01. The estimated EPS forecast for the next fiscal year is $0.47 and is expected to report on February 11th, 2020.

To read the full Lattice Semiconductor Corporation (LSCC) report, download it here: http://Capital-Review.com/register/?so=LSCC

-----------------------------------------

ZIOPHARM ONCOLOGY INC (ZIOP) REPORT OVERVIEW

ZIOPHARM Oncology's Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, ZIOPHARM Oncology reported revenue of $6.39MM vs $6.86MM (down 6.88%) and analysts estimated basic earnings per share -$0.53 vs -$1.32. Analysts expect earnings to be released on March 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.13. The estimated EPS forecast for the next fiscal year is -$0.32 and is expected to report on March 7th, 2019.

To read the full ZIOPHARM Oncology Inc (ZIOP) report, download it here: http://Capital-Review.com/register/?so=ZIOP

-----------------------------------------

FERRO CORPORATION (FOE) REPORT OVERVIEW

Ferro's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Ferro reported revenue of $395.16MM vs $350.01MM (up 12.90%) and analysts estimated basic earnings per share $0.19 vs $0.27 (down 29.63%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ferro reported revenue of $1,396.74MM vs $1,145.29MM (up 21.96%) and analysts estimated basic earnings per share $0.68 vs -$0.25. Analysts expect earnings to be released on February 27th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.29. The estimated EPS forecast for the next fiscal year is $1.70 and is expected to report on February 27th, 2019.

To read the full Ferro Corporation (FOE) report, download it here: http://Capital-Review.com/register/?so=FOE

-----------------------------------------

SYNNEX CORPORATION (SNX) REPORT OVERVIEW

SYNNEX's Recent Financial Performance

For the three months ended November 30th, 2018 vs November 30th, 2017, SYNNEX reported revenue of $5,622.20MM vs $5,311.88MM (up 5.84%) and basic earnings per share $2.52 vs $2.28 (up 10.53%). For the twelve months ended November 30th, 2018 vs November 30th, 2017, SYNNEX reported revenue of $20,053.76MM vs $17,045.70MM (up 17.65%) and analysts estimated basic earnings per share $7.23 vs $7.54 (down 4.11%). Analysts expect earnings to be released on April 4th, 2019. The report will be for the fiscal period ending February 28th, 2019. The reported EPS for the same quarter last year was $2.14. The estimated EPS forecast for the next fiscal year is $12.64 and is expected to report on January 9th, 2020.

To read the full SYNNEX Corporation (SNX) report, download it here: http://Capital-Review.com/register/?so=SNX

-----------------------------------------

AXOGEN, INC. (AXGN) REPORT OVERVIEW

AxoGen's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, AxoGen reported revenue of $22.66MM vs $16.05MM (up 41.22%) and analysts estimated basic earnings per share -$0.11 vs -$0.06. For the twelve months ended December 31st, 2017 vs December 31st, 2016, AxoGen reported revenue of $60.43MM vs $41.11MM (up 47.00%) and analysts estimated basic earnings per share -$0.31 vs -$0.47. Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.07. The estimated EPS forecast for the next fiscal year is -$0.49 and is expected to report on February 26th, 2019.

To read the full AxoGen, Inc. (AXGN) report, download it here: http://Capital-Review.com/register/?so=AXGN

-----------------------------------------

TWIN DISC, INCORPORATED (TWIN) REPORT OVERVIEW

Twin Disc's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Twin Disc reported revenue of $78.11MM vs $56.55MM (up 38.13%) and analysts estimated basic earnings per share $0.31 vs -$0.36. For the twelve months ended June 30th, 2018 vs June 30th, 2017, Twin Disc reported revenue of $240.73MM vs $168.18MM (up 43.14%) and analysts estimated basic earnings per share $0.82 vs -$0.56. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.37. The estimated EPS forecast for the next fiscal year is $1.82 and is expected to report on August 5th, 2019.

To read the full Twin Disc, Incorporated (TWIN) report, download it here: http://Capital-Review.com/register/?so=TWIN

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Nicole Garrens, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.